TY - JOUR
T1 - Respondent and item level patterns of response of aripiprazole in the acute treatment of pediatric bipolar i disorder
AU - Findling, Robert L.
AU - Youngstrom, Eric A.
AU - Zhao, Joan
AU - Marcus, Ron
AU - Andersson, Candace
AU - McQuade, Robert
AU - Mankoski, Raymond
PY - 2012/12/20
Y1 - 2012/12/20
N2 - Background: Few studies have evaluated the value of a parent- and subject-rated scale in detecting symptom change in response to pharmacologic treatment. Methods: This was a post-hoc analysis of data from a 4-week, randomized, double-blind, placebo-controlled study to evaluate which informants detect response to treatment with aripiprazole in pediatric subjects experiencing a mixed or manic episode associated with bipolar I disorder. Efficacy assessments included clinician-rated scales and the parent- and subject-rated 10-item General Behavior Inventory Mania (GBI-M10) and Depression (GBI-D10) scales. Cohen's d quantified effect sizes for total scale scores and individual line items. Results: Parent-GBI-M10 total, clinician-rated Young Mania Rating Scale (YMRS) total, and Clinical Global Impression-Bipolar Disorder (CGI-BP) Mania scores produced similar effect sizes, suggesting that the parent-GBI-M10 is sensitive to treatment-related improvements in manic symptoms. Aripiprazole improved a broad spectrum of parent-rated mania symptoms; six parent-GBI-M10 line item effect sizes were moderate (>0.5) in at least one of the two aripiprazole treatment arms (10 or 30 mg/day). Subject-completed GBI-M10 line item effect sizes were consistently smaller, indicating that the subjects' experience of treatment effects were less pronounced. Limitations: Study inclusion/exclusion criteria may limit generalizability of these findings. Conclusions: Parent ratings of mania severity were in agreement with clinician ratings, indicating that parent-rated assessments can be valuable in detecting symptom change over the course of treatment. These data support the use of the parent-GBI-M10 as an outcome measure in research and clinical settings.
AB - Background: Few studies have evaluated the value of a parent- and subject-rated scale in detecting symptom change in response to pharmacologic treatment. Methods: This was a post-hoc analysis of data from a 4-week, randomized, double-blind, placebo-controlled study to evaluate which informants detect response to treatment with aripiprazole in pediatric subjects experiencing a mixed or manic episode associated with bipolar I disorder. Efficacy assessments included clinician-rated scales and the parent- and subject-rated 10-item General Behavior Inventory Mania (GBI-M10) and Depression (GBI-D10) scales. Cohen's d quantified effect sizes for total scale scores and individual line items. Results: Parent-GBI-M10 total, clinician-rated Young Mania Rating Scale (YMRS) total, and Clinical Global Impression-Bipolar Disorder (CGI-BP) Mania scores produced similar effect sizes, suggesting that the parent-GBI-M10 is sensitive to treatment-related improvements in manic symptoms. Aripiprazole improved a broad spectrum of parent-rated mania symptoms; six parent-GBI-M10 line item effect sizes were moderate (>0.5) in at least one of the two aripiprazole treatment arms (10 or 30 mg/day). Subject-completed GBI-M10 line item effect sizes were consistently smaller, indicating that the subjects' experience of treatment effects were less pronounced. Limitations: Study inclusion/exclusion criteria may limit generalizability of these findings. Conclusions: Parent ratings of mania severity were in agreement with clinician ratings, indicating that parent-rated assessments can be valuable in detecting symptom change over the course of treatment. These data support the use of the parent-GBI-M10 as an outcome measure in research and clinical settings.
KW - Bipolar I disorder
KW - Clinical Global Impression
KW - Clinician-rating
KW - General Behavior Inventory
KW - Parent-rating
KW - Young Mania Rating Scale
UR - http://www.scopus.com/inward/record.url?scp=84869495587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869495587&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2012.04.033
DO - 10.1016/j.jad.2012.04.033
M3 - Article
C2 - 23044285
AN - SCOPUS:84869495587
VL - 143
SP - 231
EP - 235
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
SN - 0165-0327
IS - 1-3
ER -